Trials / Completed
CompletedNCT01322451
Oral Bioavailability of Two Solid Formulations of GLPG0259.
A Randomized, Open Label, 2-way Crossover Study to Compare the Oral Bioavailability of 2 Solid Dose Formulations of GLPG0259 After Single-dose Intake in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the relative bioavailability of two solid oral formulations of GLPG0259 administered after a meal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG0259 fumarate | single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate |
| DRUG | GLPG0259 free base | single oral dose, GLPG0259, 50 mg solid formulation |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2010-12-01
- Completion
- 2011-01-01
- First posted
- 2011-03-24
- Last updated
- 2011-03-24
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01322451. Inclusion in this directory is not an endorsement.